Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LifeStance Health (LFST) Depreciation & Amortization (CF): 2020-2025

Historic Depreciation & Amortization (CF) for LifeStance Health (LFST) over the last 6 years, with Q3 2025 value amounting to $13.6 million.

  • LifeStance Health's Depreciation & Amortization (CF) fell 1030.76% to $13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.0 million, marking a year-over-year decrease of 2867.15%. This contributed to the annual value of $71.0 million for FY2024, which is 1179.43% down from last year.
  • As of Q3 2025, LifeStance Health's Depreciation & Amortization (CF) stood at $13.6 million, which was down 1030.76% from $14.0 million recorded in Q2 2025.
  • Over the past 5 years, LifeStance Health's Depreciation & Amortization (CF) peaked at $22.6 million during Q1 2024, and registered a low of $12.2 million during Q1 2021.
  • Its 5-year average for Depreciation & Amortization (CF) is $16.6 million, with a median of $15.7 million in 2022.
  • Per our database at Business Quant, LifeStance Health's Depreciation & Amortization (CF) soared by 13516.2% in 2021 and then crashed by 3903.56% in 2025.
  • Quarter analysis of 5 years shows LifeStance Health's Depreciation & Amortization (CF) stood at $15.4 million in 2021, then increased by 22.99% to $18.9 million in 2022, then increased by 17.63% to $22.2 million in 2023, then tumbled by 33.96% to $14.7 million in 2024, then decreased by 7.59% to $13.6 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $13.6 million for Q3 2025, versus $14.0 million for Q2 2025 and $13.8 million for Q1 2025.